Analysts have been eager to weigh in on the Healthcare sector with new ratings on Xenon (XENE – Research Report), Biohaven Ltd. (BHVN – Research Report) and Arrowhead Pharmaceuticals (ARWR – Research Report).
Xenon (XENE)
In a report issued on May 9, Marc Goodman from Leerink Partners reiterated a Buy rating on Xenon, with a price target of $50.00. The company’s shares closed last Monday at $40.48.
According to TipRanks.com, Goodman is a 4-star analyst with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Xenon with a $57.73 average price target, a 40.6% upside from current levels. In a report issued on May 9, RBC Capital also maintained a Buy rating on the stock with a $55.00 price target.
See today’s best-performing stocks on TipRanks >>
Biohaven Ltd. (BHVN)
Robert W. Baird analyst Brian Skorney maintained a Buy rating on Biohaven Ltd. on May 9 and set a price target of $58.00. The company’s shares closed last Monday at $33.78.
According to TipRanks.com, Skorney is a 2-star analyst with an average return of
Currently, the analyst consensus on Biohaven Ltd. is a Strong Buy with an average price target of $58.88, representing a 66.0% upside. In a report issued on April 25, RBC Capital also maintained a Buy rating on the stock with a $61.00 price target.
Arrowhead Pharmaceuticals (ARWR)
In a report issued on May 9, Mani Foroohar from Leerink Partners reiterated a Hold rating on Arrowhead Pharmaceuticals, with a price target of $27.00. The company’s shares closed last Monday at $22.06, close to its 52-week low of $20.67.
According to TipRanks.com, Foroohar has 0 stars on 0-5 stars ranking scale with an average return of
Currently, the analyst consensus on Arrowhead Pharmaceuticals is a Moderate Buy with an average price target of $47.50, which is an 112.6% upside from current levels. In a report released yesterday, Morgan Stanley also maintained a Hold rating on the stock with a $27.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on XENE:
- Xenon Pharmaceuticals price target lowered to $50 from $51 at Wedbush
- Xenon Pharmaceuticals price target lowered to $60 from $62 at Citi
- Xenon Pharmaceuticals Advances Drug Trials
- Xenon Pharmaceuticals: Engaging Investors with Regular Updates
- Xenon Pharmaceuticals reports Q1 EPS (62c), consensus (66c)
